Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
ANAHEIM, CA, April 26, 2018 -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, as well as actor Jeremy Miller, best known for his role as Ben Seaver on the hit TV show Growing Pains, appeared as guests on Varney & Co on Fox Business.
Mr. Miller discussed his personal experience with alcoholism and how the implant has been “an absolute game changer” after trying other treatments, unsuccessfully. In discussing the implant, he noted, “Within hours I started noticing the effects, and what you notice is what’s not there – that constant obsessive need, it just kind of vanished. It’s like a light switch turned off for me.”
During the interview, Mr. Granier discussed the advantages of the Company’s sustained release naltrexone implant, including its efficacy, price points and recent meeting with the FDA regarding its plans to submit the implant, named BICX102, for marketing clearance in order to gain wider payor acceptance.
The segment can be viewed online at http://www.foxbusiness.com/shows/varney-co.html.
Varney & Co. is a daily morning news/talk program hosted by British-American economic and political commentator Stuart Varney on Fox Business on weekdays 9 AM - 12 PM ET. The show includes market coverage, current events coverage, and interviews and commentary with Wall Street experts.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc. [email protected] 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 [email protected]
